UTHR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
UTHR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
United Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $400 Mil. United Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $200 Mil. United Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $1,708 Mil. United Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.35.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for United Therapeutics's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of United Therapeutics was 1.21. The lowest was -11.35. And the median was 0.41.
The historical data trend for United Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -11.35 | 1.12 | 1.21 | 0.77 | 0.51 |
United Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | 0.63 | 0.55 | 0.53 | 0.54 | 0.35 |
For the Biotechnology subindustry, United Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, United Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
United Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (400 | + | 300) | / | 1386.8 | |
= | 0.50 |
United Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (400 | + | 200) | / | 1707.6 | |
= | 0.35 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.
United Therapeutics (NAS:UTHR) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of United Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul A Mahon | officer: EVP & General Counsel | |
Nilda Mesa | director | C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910 |
Christopher Causey | director | |
Martine A Rothblatt | director, officer: Chief Executive Officer | |
Louis W Sullivan | director | |
Judy D. Olian | director | 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067 |
Michael Benkowitz | officer: President and COO | C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910 |
Christopher Patusky | director | |
Raymond Dwek | director | |
Linda Maxwell | director | 1040 SPRING STREET, SILVER SPRING NC 27709 |
Tommy G Thompson | director | 7711 CARONDELET, ST. LOUIS MO 63105 |
Katherine J Klein | director | STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104 |
Richard Giltner | director | C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009 |
Roger Jeffs | director, officer: President and COO | |
David Zaccardelli | officer: EVP & Chief Operating Officer | 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069 |
From GuruFocus
By Business Wire • 07-24-2023
By GuruFocus Research • 12-22-2023
By GuruFocus Research • 10-21-2023
By GuruFocus Research • 01-06-2024
By GuruFocus Research • 12-19-2023
By GuruFocus Research • 09-23-2023
By Business Wire • 12-29-2023
By Business Wire • 09-01-2023
By GuruFocus Research • 11-01-2023
By GuruFocus Research • 01-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.